Checkpoint inhibitor therapy: Immune-related adverse event management
Department
Nursing
Document Type
Article
Publication Title
Nursing
Abstract
Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.
First Page
26
Last Page
33
DOI
10.1097/NSG.0000000000000083
Volume
54
Issue
11
Publication Date
11-1-2024
PubMed ID
39497665
Recommended Citation
Davis, L., Casselbury, M., & Wilson, S. (2024). Checkpoint inhibitor therapy: Immune-related adverse event management. Nursing, 54 (11), 26-33. https://doi.org/10.1097/NSG.0000000000000083
COinS
